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Abstract
Background: A growing number of arenaviruses can cause a devastating viral hemorrhagic fever (VHF) syndrome. They
pose a public health threat as emerging viruses and because of their potential use as bioterror agents. All of the highly
pathogenic New World arenaviruses (NWA) phylogenetically segregate into clade B and require maximum biosafety
containment facilities for their study. Tacaribe virus (TCRV) is a nonpathogenic member of clade B that is closely related to
the VHF arenaviruses at the amino acid level. Despite this relatedness, TCRV lacks the ability to antagonize the host
interferon (IFN) response, which likely contributes to its inability to cause disease in animals other than newborn mice.
Methodology/Principal Findings: Here we describe a new mouse model based on TCRV challenge of AG129 IFN-a/b and -c
receptor-deficient mice. Titration of the virus by intraperitoneal (i.p.) challenge of AG129 mice resulted in an LD50 of ,100
fifty percent cell culture infectious doses. Virus replication was evident in the serum, liver, lung, spleen, and brain 4–8 days
after inoculation. MY-24, an aristeromycin derivative active against TCRV in cell culture at 0.9 mM, administered i.p. once
daily for 7 days, offered highly significant (P,0.001) protection against mortality in the AG129 mouse TCRV infection model,
without appreciably reducing viral burden. In contrast, in a hamster model of arenaviral hemorrhagic fever based on
challenge with clade A Pichinde arenavirus, MY-24 did not offer significant protection against mortality.
Conclusions/Significance: MY-24 is believed to act as an inhibitor of S-adenosyl-L-homocysteine hydrolase, but our findings
suggest that it may ameliorate disease by blunting the effects of the host response that play a role in disease pathogenesis.
The new AG129 mouse TCRV infection model provides a safe and cost-effective means to conduct early-stage pre-clinical
evaluations of candidate antiviral therapies that target clade B arenaviruses.
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Introduction
Junı ´n and other South American hemorrhagic fever-causing
viruses pose a considerable public health threat as emerging
infectious disease agents and because of their potential for
intentional release [1]. All of the highly pathogenic New World
arenaviruses (NWA; Junı ´n, Machupo, Guanarito, Sabia), includ-
ing the recently identified Chapare virus, phylogenetically
segregate into clade B [2], and require maximum biosafety level
4 (BSL-4) containment facilities for their study. Presently, there are
no clade B arenavirus infection models outside of newborn mice
suitable for early stage antiviral drug development and proof-of-
concept studies. There are several guinea pig and nonhuman
primate models based on infection with authentic BSL-4
arenaviral hemorrhagic fever agents, but they are not readily
available to most researchers [3]. Moreover, studies in BSL-4
containment and with larger animal species are cost-prohibitive
for use in early pre-clinical drug development.
Tacaribe virus (TCRV) is a nonpathogenic member of clade B
that is ,70% identical to Junı ´n virus (JUNV) at the amino acid
level [4]. However, despite its relatedness to the highly pathogenic
NWA, TCRV lacks the ability to antagonize the host interferon
(IFN) response [5], which likely contributes greatly to its inability
to cause disease in mature animals. Because of the apathogenicity
of TCRV in mice and other rodents, a newborn mouse model was
established to evaluate lead antiviral compounds in vivo, primarily
with the intent to demonstrate proof-of-concept in a Clade B
NWA model [4,6]. Due to the many challenges of working with
newborn mice and their underdeveloped cellular and immune
response to infectious agents, an alternative model to study clade B
arenavirus infection biology and evaluate candidate therapies is
needed.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12760AG129 IFN-a/b and -c receptor knockout (KO) mice were
originally described to have increased susceptibility to severe
infection with the prototypical arenavirus, lymphocytic chorio-
meningitis virus (LCMV), as well as vaccinia virus [7]. Recently,
the AG129 mice were used to develop a dengue hemorrhagic fever
disease model that manifests vascular leak, thus, more closely
resembling the human condition [8]. In a study investigating the
contributions of type I and II IFN antiviral responses to Sindbis
virus infection, wild-type and IFN-c receptor KO (G129) mice
were found to be resistant to challenge, whereas the IFN-a/b
receptor KO (A129) and the double KO AG129 mice succumbed
to infection [9]. Importantly, the AG129 mice produced a lethal
viral hemorrhagic fever (VHF)-like disease not observed in the
Sindbis virus-infected A129 mice. Because TCRV does not disrupt
IFN production [5], the AG129 mice may provide fertile ground
for viral replication that culminates in a lethal viscerotropic
disease, thereby providing a model that can be used to evaluate
antiviral drug candidates for the treatment of acute arenaviral
infections.
To date, there are limited options for treating JUNV infection in
cases of Argentine hemorrhagic fever. Immune plasma has been
reported to be effective at reducing case-fatality rates when
administered within a week from the onset of illness [10]. In a
clinical trial with limited enrollment, ribavirin therapy had an
antiviral effect on several measured disease parameters including
viral load and delay in time of death in patients who succumbed
[11]. Notably, however, both immune plasma and ribavirin
treatments have been associated with neurologic sequelae following
the resolution of the acute phase of the disease [12]. The use of
ribavirin has also been explored in several cases of Bolivian
hemorrhagic fever [13], but larger numbers of patients are needed
to convincingly demonstrate efficacy. Finally, in a landmark study
wherein ribavirin was used to treat sever cases of Lassa fever,
significant efficacy was demonstrated [14]. Notably, however,
ribavirin lacks specificity [15], is associated with considerable
toxicity [16], and is not approved by the FDA for the indication of
treating any form of arenaviral hemorrhagic fever [1].
There are several new antiviral drug candidates that have
demonstrated efficacy in small animal models of acute NWA
infection. Favipiravir (T-705) has been shown to be highly effective
in the hamster Pichinde virus (PICV) model of arenaviral
hemorrhagic fever [17], and is capable of treating advanced
disease [18]. Presumably, the mode of antiviral action in
arenaviruses is through inhibition of the viral polymerase, as has
been shown for influenza virus [19]. ST-294, a potent inhibitor of
NWA membrane fusion has also demonstrated activity in a
newborn mouse TCRV infection model [4].
Several biologics that enhance the host antiviral response are
also being considered. Although Lassa fever is thought to be
resistant to the effects of type I IFN [20], a recent study
demonstrated sensitivity of several strains Lassa virus to IFN-a
and -c in cell culture [21]. Moreover, treatment with consensus
IFN-a, alone or in combination with ribavirin has proven effective
in the hamster PICV infection model [22,23]. A novel therapy
based on the targeting of anionic phospholipids exposed on
infected cells and virions has shown promise in studies employing a
guinea pig model based on infection with an adapted PICV [24].
Despite the present efforts to develop therapies for the treatment of
arenaviral hemorrhagic fevers, most are in the early stages of
development, and new classes of inhibitors will most certainly be
needed.
Carbocyclic nucleosides have provided a foundation for
discovering new biological agents, including antivirals [25,26].
Among this class of compounds, aristeromycin (Figure 1, 1), which
is the naturally occurring carbocylic nucleoside analog of
adenosine (Figure 1, 2) [27], has been particularly valuable in
the search for new antivirals because of its inhibition of host cell S-
adenosylhomocysteine hydrolases [28], an enzyme that plays a
role in metabolic methylations requiring S-adenosylmethionine as
enzymatic cofactor [29]. However, the potential of aristeromycin
is limited by its ready intracellular conversion to the 59-nucleotides
that renders it toxic [30,31,32,33]. As part of a study to circumvent
this toxicity, 59-homoaristeromycin (Figure 1, 3) was reported to
have activity against vaccinia, cowpox, and monkeypox viruses
[34]. In the following, we report the details of our synthesis of 59-
homoaristeromycin, referred to herein as MY-24, and its
evaluation in a newly developed AG129 mouse TCRV infection
model.
Materials and Methods
Ethics statement
All animal procedures complied with USDA guidelines and
were conducted at the AAALAC-accredited Laboratory Animal
Research Center at Utah State University under protocols 1229
and 1425, approved by the Utah State University Institutional
Animal Care and Use Committee.
Animals
Four to seven week-old AG129 IFN-a/b and -c receptor-
deficient mice were obtained from Dr. Justin Julander’s breeding
colony at Utah State University. They were fed irradiated mouse
chow and autoclaved water ad libitum. Female 60–100 g golden
Syrian hamsters were obtained from Charles River Laboratories
(Wilmington, MA) and acclimated for a minimum of 6 days prior
to experimentation. They were fed standard hamster chow and
tap water ad libitum.
Viruses
TCRV, strain TRVL 11573, was obtained from American
Type Culture Collection (ATCC; Manassas, VA). The virus stock
(2 passages in Vero 76 African green monkey kidney cells) used
was from a clarified cell culture lysate preparation concentrated
using an Amicon stirred ultrafiltration cell (Millipore, Danvers,
MA). The JUNV vaccine strain, Candid 1, was provided by Dr.
Robert Tesh (World Reference Center for Emerging Viruses and
Arboviruses, University of Texas Medical Branch, Galveston,
TX). PICV, strain An 4763, was provided by Dr. David Gangemi
Figure 1. Chemical structure of MY-24 and derivatives.
Aristeromycin (1), adenosine (2), 59-homoaristeromycin (MY-24)(3).
doi:10.1371/journal.pone.0012760.g001
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passaged once through hamsters and once in Vero (African green
monkey kidney) cells. PICV stocks for challenge efficacy studies
were prepared from pooled livers harvested from infected
hamsters. Stocks for cell culture studies were from clarified Vero
cell culture lysates. JUNV was amplified in Vero cells and the virus
stock was prepared from clarified cell culture lysates.
Compounds
The synthesis of MY-24 has previously been reported in
communication form [34]. However, the experimental details
have not been described. Due to the biological potential of MY-24,
the detailed procedures are provided as supporting methodology
(Figure S1 and Text S1). Ribavirin was supplied by ICN
Pharmaceuticals, Inc. (Costa Mesa, CA). For in vivo studies, both
MY-24 and ribavirin were dissolved in sterile saline solution and
administered by intraperitoneal (i.p.) injection.
Cell culture antiviral assays
Vero and Vero 76 cells were obtained from ATCC and
maintained in minimal essential medium (MEM) supplemented
with 0.18% NaHCO3 and 10% fetal bovine serum (FBS; Hyclone
Thermo Scientific, Logan, UT). Cell cultures in 96-well microtiter
plates were ,80% confluent at time of infection with 5 cell culture
50% infectious doses (CCID50) of JUNV, PICV, or TCRV
prepared in MEM containing 2% FBS. Varying concentrations of
MY-24 and ribavirin (positive control) solubilized in MEM were
added to test wells at the time of infection. To determine cell
cytotoxicity, compounds were added to cultures devoid of virus
infection. Plates were incubated at 37uC, 5% CO2, until virus-
infected mock-treated control wells were observed to have
maximal viral cytopathic effect CPE (,7 to 8 days), at which
time cell viability was determined by neutral red (NR) dye uptake
as previously described [17]. The mean effective concentration
(EC50) of each compound and the concentration that reduced cell
viability by 50% (CC50) were determined by regression analysis.
Virus yield reduction (VYR) experiments were conducted to
determine the effect of MY-24 on infectious virus. Concentrations
of compound that reduce virus yield by 1 log10 (EC90) were
determined by regression analysis. Selectivity index (SI) values
were calculated as the CC50/EC50 for the CPE reduction (CPER)
NR-based assays, and as CC50/EC90 for the VYR assays.
TCRV AG129 mouse model development and challenge
efficacy studies
For all studies mice were age and gender matched so that the
group compositions would be similar within experiments. In the
initial experiments, weights were not measured to limit handling
and exposure of the immunocompromised AG129 mice. For the
titration study, mice in each group were challenged by
intraperitoneal (i.p.) injection with varying CCID50 of TCRV
spanning 6 orders of magnitude and observed for 21 days. Because
several of the mice continued to appear ill on day 21, we collected
liver, spleen, brain, and serum for virus titer determination, as
described below.
A longitudinal analysis of viral titers and ALT levels was
performed by sorting mice into groups of 3 to 6 animals and
challenging them with ,200 CCID50 of TCRV. The mice were
observed for 1 to 12 days, and sacrificed on days 1–6, 8, 10, and
12. The day-12 group had 6 animals in anticipation of several
animals succumbing prior to time of sacrifice. Serum was assayed
for viral burden and ALT levels. Tissues were collected for liver,
lung, spleen, and brain virus titer determination, as described
below. Histopathology was also determined at various times
during the course of infection. Tissue sections were fixed in
formalin and sent to the Utah Veterinary Diagnostic Laboratory
(Logan, UT) for histological examination.
In the TCRV challenge MY-24 efficacy experiments, mice were
sorted into groups of 10 to 15 animals for drug treatment groups
and 15 to 25 for the placebo groups. MY-24 treatments were
administered starting 4 h prior or 1, 3 or 5 days after challenge
with 200 CCID50 of TCRV. Animals were treated i.p. once daily
for 7 days with 25 to 150 mg/kg/day of MY-24, 50 mg/kg/day
ribavirin, or saline placebo. In one of the experiments, 5 mice from
each group were sacrificed on day 8 of infection. Serum, liver,
lung, spleen, and brain samples were collected for assaying virus
titers as described below. The mice were observed for 3 to 4 weeks
for signs of morbidity and mortality. Three to six sham-infected
mice were included as normal controls for the infections. A subset
of uninfected animals treated with 75 or 150 mg/kg/day of MY-
24 was also included in the first experiment to assess possible
toxicity.
Hamster PICV challenge MY-24 efficacy studies
Hamsters were weighed on the morning of treatment and
grouped so that the average hamster weight per cage across the
entire experiment varied by less than 5 grams. Animals were
treated as indicated with 5 to 100 mg/kg/day doses of MY-24 or
vehicle placebo 4 h prior to i.p. challenge with ,2 plaque-forming
units (PFU) of PICV. Ribavirin (40 mg/kg/day) was included as a
positive control and given by the same route and following the
same schedule. Five hamsters from each group (up to 10 for the
placebo groups) were sacrificed on day 7 of infection and sera were
collected for assaying alanine aminotransferase activity and virus
titers were determined for both liver and serum samples as
described below. The remaining 10 animals (20 for the placebo
group) were observed 21 days for mortality. Three to four sham-
infected controls were included for comparison to establish
baselines for all test parameters. In separate studies conducted in
uninfected hamsters, tolerability of doses up to 100 mg/kg/day of
MY-24 was evaluated prior to challenge efficacy experiments.
Tissue virus titer determinations
Virus titers were assayed using an infectious cell culture assay as
previously described [17]. Briefly, a specific volume of tissue
homogenate or serum was serially diluted and added to triplicate
wells of Vero 76 cell monolayers in 96-well microplates. The viral
CPE was determined 7–8 days post-virus inoculation and the 50%
endpoints were calculated as described [35]. The assay detection
ranges were 2.8–9.5 log10 CCID50/g of tissue or 1.8–8.5 log10
CCID50/ml of serum. In samples presenting with undetectable
tissue or serum virus, a value of ,2.8 or 1.8 log10 was assigned,
respectively. Conversely, in cases wherein virus exceeded the
detection range, a value of.9.5 or 8.5 log10 was assigned. For
graphic representation and statistical analysis, respective values of
1.8, 2.8, 8.5, or 9.5 log10 were assigned as needed for samples with
undetectable or saturated virus levels.
Serum alanine aminotransferase (ALT) determinations
Detection of ALT in serum is an indirect method for evaluating
liver damage. Per the manufacturer’s recommendations, serum
ALT levels were measured using the ALT (SGPT) Reagent Set
purchased from Pointe Scientific, Inc. (Lincoln Park, MI). The
reagent volumes were adjusted for analysis on 96-well microplates.
MY-24 Efficacy in TCRV Model
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Kaplan-Meier survival plots and all statistical evaluations were
done using Prism (GraphPad Software, CA). The log-rank test was
employed for survival analysis. For analyzing differences in viral
titers and ALT levels, a one-way analysis of variance (ANOVA)
with Newman-Keuls post test or the Kruskal-Wallis test with the
Dunn’s post test was performed based on Gaussian distribution of
the data. The Mann-Whitney test (two-tailed) was used for
comparing mean day of death.
Results
In vitro anti-arenavirus activity of MY-24
The activity of the aristeromycin derivative, MY-24, was
investigated in several cell culture-based arenavirus infection
model systems. As shown in Table 1, MY-24 demonstrated
moderate activity against TCRV, JUNV, and PICV by VYR with
EC90 values ranging from 0.9 to 2.4 mM. Notably, by CPER assay,
the clade B arenaviruses (TCRV and JUNV) were found to be
more sensitive to MY-24. Ribavirin, included as a positive control,
was active in the range of 8–16 mM versus the same panel of
arenaviruses. MY-24 had markedly lower CC50 values compared
to ribavirin, resulting a 4-fold difference in VYR SI values ranging
from 12 to 31 for MY-24 and 119 to 135 for ribavirin.
Characterization of TCRV infection in AG129 mice
Because MY-24 demonstrated better antiviral activity against
the more medically relevant clade B arenaviruses in cell culture
(Table 1), we pursued the development of a rodent model based on
challenge with TCRV. We initially challenged weanling hamsters
i.p. with up to 10
6 CCID50 of TCRV and found them to be
refractory to infection, with no apparent signs of illness or weight
loss (data not shown). We next explored TCRV model
development in AG129 IFN-a/b and -c receptor-deficient mice.
We hypothesized that devoid of the critical IFN antiviral response,
these mice would be susceptible to productive TCRV infection. As
shown in Figure 2, the AG129 mice were sensitive to the virus at
varying degrees based on the viral inoculum, with disease
progressing slowly and animals first succumbing on day 10 of
infection.
Because some of the surviving mice continued to show varying
degrees of mild to moderate disease signs (lethargy, ruffled fur, and
hunched posture) towards the final days of the 3 week study, we
sacrificed all surviving animals on day 21 to measure systemic viral
burden and tissue titers. In the 4 surviving animals that were
challenged with 2610
3 or greater CCID50, all had 5 to 6 log10 of
virus in the brain and spleen, 2 of 4 had 5 log10 of liver virus, and 3
of 4 had 3.5 to 5 log10 of serum virus (data not shown). Only
,20% of the samples collected from the surviving mice challenged
with 20 or 2 CCID50 of TCRV had detectable levels of virus on
day 21.
A follow-up study was conducted to characterize the progression
of TCRV infection during the acute phase of disease in AG129
mice. As seen in Figure 3A–E, all tissues examined harbored virus.
Table 1. In vitro inhibitory effects of MY-24 and ribavirin against arenaviruses
a.
MY-24
c Ribavirin
c
Virus Assay
b
CC50 ±
SD EC50/90 ± SD SI
d CC50 ± SD EC50/90 ± SD SI
d
TCRV CPER 2868.2 0.960.2 31 11066356 1262.5 92
VYR 0.960.2 31 8.262.0 135
JUNV CPER 3365.7 2.461.2 14 11886356 1165.7 108
VYR 1.160.6 30 1063.9 119
PICV CPER 28615 16610 2 10246217 1668.2 64
VYR 2.461.2 12 7.862.5 132
aData are the mean and standard deviations from 3 separate experiments in Vero (JUNV and PICV) or Vero 76 (TCRV) cells.
bCytopathic effect reduction (CPER) based on neutral red dye uptake by viable cells; virus yield reduction (VYR).
cCC50 and EC50 values are inmM.
dSelectivity index (SI) = CC50/EC50/90.
doi:10.1371/journal.pone.0012760.t001
Figure 2. Survival of AG129 mice challenged with TCRV. Groups
of 5 mice/group were inoculated with the indicated CCID50 dose of
TCRV. Mortality was monitored over a 21-day period. Percent survival
for the 2,000 CCID50 group was based on 4 animals due to the loss of
one animal on day 2 from causes not believed to be related to TCRV
infection.
doi:10.1371/journal.pone.0012760.g002
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was the spleen, with ,6 log10 CCID50/g on day 4 of the infection,
and sustained virus burden out to day 12 (Figure 3D). In several
spleen samples collected on and after day 8, white pustule-like
spots and a pale light color were evident by gross visual
examination. Virus first became apparent systemically on day 5
in 2 of the 3 mice, with sporadic titers through day 10, and a spike
up to ,7 log10 CCID50/ml detected on day 12 (Figure 3A).
Remarkably, liver virus titer went from undetectable on day 5 to
,6–7 log10 CCID50/g on days 6–12 (Figure 3B). A slight hint of
lung virus could be detected as early as day 5, with a substantial
incremental increase thereafter of approximately 1 log10/day as
disease progressed (Figure 3C). TCRV was found in the brain in 7
of 9 animals on day 8 and later (Figure 3E). It is possible that virus
was present as early as day 7 since we did not include that time
point in the analysis. Overall, ALT levels were fairly normal
despite considerable viral burden; however, a few animals did
show some elevation on days 10 and 12 (Figure 3F). Considering
that the mean day of death in animals that succumb from TCRV
infection is ,12 days, with a range of 10–20 days, it is not
surprising to see peak infectious TCRV loads at day 12. Notably,
the day-12 analysis is likely an underestimate of the viral burden
since the 3 sickest animals had succumbed prior to the time of
sample collection.
Obvious evidence of disease was not histologically observed
until day 8 of infection. Typical liver lesions included moderate
numbers of portal lymphocytes and histiocytes (Figure 4A) and
scattered degenerate/necrotic hepatocytes surrounded by small
numbers of neutrophils or lymphocytes. Spleens of infected mice
had hyperplastic follicles, follicular lympholysis and increased
Figure 3. Time course analysis of tissue TCRV titers and ALT levels in AG129 mice. Groups of 3 animals were sacrificed on the specified
days during infection for analysis of A) serum, B) liver, C) lung, D) spleen, and E) brain virus titers, and F) serum ALT concentration. The day-12 group
started with 6 animals, with 3 succumbing prior to time of sacrifice.
doi:10.1371/journal.pone.0012760.g003
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10 livers and spleens had similar pathology to that described for
day-8 tissue samples (data not shown). There was no kidney or
brain pathology associated with advanced TCRV infection in the
AG129 mice. However, there was mild perivascular edema with
small numbers of mixed inflammatory cells surrounding larger
vessels in lungs of ,25% of the animals on days 8 and 10 of
infection (data not shown). Taken together, the virus titer and
histological findings indicate that TCRV-induced disease pro-
gresses slowly in the AG129 mice, providing an ample window of
therapeutic opportunity to assess anti-arenaviral drug candidates
in a murine system.
Evaluation of MY-24 prophylaxis in AG129 mice
challenged with TCRV
Having gained an understanding of the natural history of
disease in the AG129 mouse TCRV mouse infection model, we
sought to evaluate MY-24 in the newly established model. MY-24
was dosed at 150 and 75 mg/kg/day i.p. for 7 days. We treated
the mice only once daily to limit handling of the type I and type II
IFN system-compromised AG129 mice. As demonstrated in
Figure 5, MY-24 treatment regimens resulted in 100% protection
against a lethal TCRV challenge dose. Ribavirin was also effective
and protected 89% of the mice from mortality. Six uninfected
mice treated in parallel with 150 mg/kg/day (n=3) or 75 mg/kg/
day (n=3) of MY-24 all survived the treatment regimen without
any signs of adverse effects.
Notably, we did observe that the infected animals treated with
MY-24 had ruffled fur and were lethargic compared to the control
animals towards the end of the study, which prompted us to weigh
them on days 18 and 21. Average group weight gain of 1.9
(150 mg/kg/day dose) and 1.1 (75 mg/kg/day dose) grams over
that period suggested to us that they were on their way to recovery.
Some of the ribavirin-treated animals also presented with ruffled
fur and one had left hind leg paralysis. These animals also gained
weight (1 g) from days 18 to 21 and appeared to be in a state of
Figure 4. Histologic examination of liver and spleen sections from TCRV-infected AG129 mice. Representative A) liver and B) spleen
histopathology on day 8 of TCRV infection in AG129 mice. C) Liver and D) spleen tissue from healthy sham-infected mice. Tissues were stained with
hematoxylin and eosin.
doi:10.1371/journal.pone.0012760.g004
Figure 5. MY-24 protects AG129 mice challenged with TCRV
from mortality. Mice were treated i.p. once daily for 7 days with the
indicated mg/kg (mpk) doses of MY-24 or ribavirin. Treatment was
initiated 4 hours prior to infection. Data shown for the high-dose MY-
24, low-dose MY-24, ribavirin, and placebo groups are based on 9, 8, 9,
and 15 animals per group, respectively. ***P,0.001 compared to saline
placebo-treated animals.
doi:10.1371/journal.pone.0012760.g005
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gained 0.9 g over that 3-day period.
A follow-up evaluation of MY-24 in the AG129 mouse TCRV
infection model was conducted to verify the results from the initial
experiment (Figure 5) and to assess the impact of the compound on
viral burden. Again, dramatic efficacy was observed in mice
treated with MY-24 in the context of survival (Figure 6A).
Complete protection was seen in the 25 and 50 mg/kg/day
groups, with only a single mouse (out of a total of 7) succumbing in
the 100-mg/kg/day group on day 22 of the infection, well after the
Figure 6. MY-24 protects AG129 mice against lethal TCRV infection despite lack of inhibition of viral replication. Mice were treated i.p.
once daily for 7 days with the indicated doses of MY-24 or ribavirin, starting 4 h prior to TCRV challenge. A) Survival data are based on 7, 10, 10, 10,
and 20 animals per group for the high-dose MY-24, intermediate dose MY-24, low-dose MY-24, ribavirin, and placebo groups, respectively. An
additional 4 to 5 mice per group were sacrificed on day 8 of infection for B) serum, C) liver, D) lung, and E) spleen virus titer determinations. **P,0.01,
***P,0.001 compared to saline placebo-treated animals.
doi:10.1371/journal.pone.0012760.g006
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Ribavirin protected 90% of challenged mice. By visual inspection
of the animals during the study, several of the ribavirin treated
animals presented with varying degrees of lethargy and ruffled fur
starting on day 12 and thereafter. This was also apparent in some
of the mice in the 100- and 50-mg/kg/day MY-24 groups on day
17 and beyond, but to a lesser degree in the 50-mg/kg/day group.
Despite their ruffled appearance, most of these animals survived
the 28-day observation period. More severe lethargy and ruffling
of fur were observed in placebo-treated animals prior to
succumbing from infection.
In addition to survival, day 8 viral loads from serum and liver,
spleen, lung (Figure 6B–E), and brain tissues (data not shown) were
also examined. Virus was present in all tissues except for brain.
Lack of detectable virus may have been due to a slower
development of brain virus titers in this particular experiment.
MY-24 did not have any impact on viral burden in the viscera,
despite robust protection in the context of overall survival. In
contrast, ribavirin was able to partially knock down titers in serum,
liver, and lung, but not spleen.
Therapeutic efficacy of MY-24 in TCRV-challenged AG129
mice
In the first two experiments, MY-24 treatment was initiated 4 h
prior to TCRV challenge. A third experiment was conducted to
investigate the therapeutic capacity of MY-24. Because TCRV
infection can spread into the brain by day 8 (and possibly day 7)
and because we did not have any information as to the ability of
MY-24 to cross the blood-brain barrier, therapeutic interventions
were started prior to day 6. As seen in Figure 7A, delayed
treatment of TCRV infection in AG129 mice was highly effective
with complete protection afforded when treatment was initiated on
or after day 3, and 90% protection in the group where treatment
started on day 1. Based on individual animal weights tracked
during the course of the experiment, mice receiving placebo
generally began to markedly lose weight during the transition from
day-6 to day-9, and the surviving mice started their recovery after
day 18 (Figure 7B–D). In contrast, the MY-24 day-1 and day-3
treatment groups maintained weight through 12 days, lost
considerable weight on days 15 and 18, followed by recovery
and weight gain by day 21 (Figure 7B, C). Interestingly, most of
the mice in the day-5 treatment initiation group were found to
have a more gradual decrease in weight through day 18, prior to
the recovery phase (Figure 7D).
We also documented ruffling of fur during the course of the
experiment. For the placebo-treated animals, this process began
on about day 7 or 8 and continued throughout the entire
experiment for the surviving animals. In the day-1 MY-24 group,
the ruffled appearance started on day 12 and persisted for most of
the animals through the end of the study. The day-3 group began
to show the ruffled appearance on day 14, but it was noted that by
day 22 the ruffling was less pronounced and improved gradually
afterwards. For the day-5 MY-24 treatment group, mild ruffling
was seen on day 16 of infection and persisted until day 21 with
minimal ruffling noted by day 22. These observations are
consistent with the individual weight change profiles shown in
Figure 7B–D. Remarkably, both the weight change data and our
observations of the mice show that the later the time of initiation,
the more efficacious the MY-24 treatment was.
Evaluation of MY-24 in hamsters challenged with PICV
We also investigated the activity of MY-24 in the well-
established hamster model of acute arenaviral disease based on
challenge with PICV. MY-24 was well-tolerated in preliminary
toxicity studies with doses tested up to 100 mg/kg/day (data not
shown). Doses ranging from 5 to 75 mg/kg/day were evaluated
in the in the first challenge efficacy experiment. As seen in
Figure 8A, there was a slight protective effect evident by the
Figure 7. Post-exposure MY-24 treatment prevents mortality in
TCRV-challenged AG129 mice and delays clinical signs of
illness. Mice (n=10/group) were treated i.p. once daily for 7 days with
75 mg/kg/day of MY-24 or placebo starting at the indicated days post
infection. A) Survival and a longitudinal analysis of B) body weight were
monitored during the course of the infection. Individual animal weights
were recorded every 3 days for 24 days, with a final weight taken at the
conclusion of the experiment. **P,0.01, ***P,0.001 compared to the
respective saline placebo-treated animals.
doi:10.1371/journal.pone.0012760.g007
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with the placebo. This was emphasized by a significant increase
in the mean day of death (P,0.05) of hamsters treated with
75 mg/kg/day (11.764.1 days), compared to the placebo group
(9.463.1). The 25- and 5-mg/kg/day doses were ineffective. A
MY-24 dose-dependent decrease in ALT was noted with the
animals that received the 75-mg/kg/day dose presenting with
significantly reduced levels (Figure 8B). Consistent with the lack
of a direct effect on viral titers seen in the TCRV AG129 mouse
infection model (Figure 6B–D), neither liver nor serum PICV
burden was reduced in the MY-24-treated hamsters compared to
animals receiving saline placebo (Figure 8C, D). The positive
control drug, ribavirin, protected 100% of challenged hamsters
from death and reduced viral burden by an average of 4–5.5
log10, and greatly minimized liver disease as reflected by baseline
ALT readings (Figure 8).
Because we observed the most robust protection at the highest
tested dose of 75 mg/kg/day, we also tested a higher dose of MY-
24. Notably, we used smaller hamsters in the subsequent studies to
reduce the MY-24 quantities needed for higher and extended 7-
day duration dosing regimens.
As in the first efficacy study, 75-mg/kg/day of MY-24 had only
a subtle protective effect primarily manifested as a delay in mean
day of death (10.662.3 days compared to 8.961.3 days for the
placebo: P,0.01) and significantly reduced liver disease as
measured by systemic ALT concentrations (3336124 IU/ml
compared to 12956483 IU/ml for the placebo: P,0.001).
Moreover, no reduction in serum or liver viral load was observed
following MY-24 treatment (data not shown). At a dose of
100 mg/kg/day, MY-24 again had no impact on the total number
of surviving hamsters, but similarly delayed the time of death
(13.464.6 days compared to 9.762.7 days for the placebo:
P,0.05). Taken together, increasing of MY-24 dosage and
extending treatment duration did not remarkably improve disease
outcome.
Discussion
MY-24 is an analog of aristeromycin, which is a potent inhibitor
of S-adenosyl-L-homocysteine (AdoHcy, SAH) hydrolase. SAH
hydrolase was first identified as an antiviral target in 1982 [36].
Since that time, a number of compounds, including aristeromycin,
Figure 8. Effect of MY-24 treatment on survival outcome, viral burden, and liver disease in PICV-infected hamsters. Animals in each
group (n=15) were treated i.p. twice daily for 6 days with MY-24 or ribavirin at the indicated mg/kg/day dose levels. A placebo-treated control group
(n=25) was included for comparison. Treatment was initiated 4 hours prior to infection and 5 animals per group were sacrificed on day 7 for
evaluation of viral burden and ALT levels. A) Survival analysis, B) serum ALT, C) liver virus titer, and D) serum virus titer. *P,0.05, **P,0.01,
***P,0.001 compared to saline placebo-treated animals.
doi:10.1371/journal.pone.0012760.g008
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number of viruses, including arenaviruses [28]. In the present
study, we have evaluated MY-24 in two small animal models of
acute arenaviral infection based on activity of the compound in
cell culture.
Despite only observing a slight protective effect in trials
employing the hamster clade A PICV infection model, MY-24
was highly efficacious in the newly developed AG129 mouse
TCRV challenge model. Because of the better cell culture activity
profile of MY-24 against the clade B arenavriuses, it was essential
to test the compound against TCRV. A recent study underscores
the need to test promising compounds targeting the clade B
arenaviral hemorrhagic viruses against TCRV in vivo. Bolken et al.
used a model based on i.p. challenge of in newborn mice [6] to
demonstrate the efficacy of a small molecule inhibitor (ST-294)
with known in vitro activity against clade B NWA, but not the more
distantly related PICV or LASV [4].
Because rodent model systems that employ newborn animals to
produce lethal infection are generally considered to be farther
removed from the human disease being modeled [3], and because
of the difficulty of working with newborn mice, we developed a
new TCRV mouse infection model based on i.p. challenge of
AG129 type I and type II IFN receptor-deficient mice. The use of
the new TCRV mouse model over the existing hamster PICV
model was also advantageous because it greatly reduced the
amount of compound required for our studies. On a mg/kg basis,
a TCRV mouse experiment would require ,5- to 8-fold less drug
to complete compared to hamster models. This can be an
important issue in early stage drug development wherein costly,
time-consuming synthesis of additional compound would be
pursued only if dictated by basic proof-of-concept studies in mice,
prior to advancing to PICV, Pirital virus [37], or BSL-4 arenaviral
hemorrhagic fever guinea pig models [38,39,40]. One must
consider however that the use of the new TCRV model is
probably better suited for investigating the activity of candidate
therapeutics that directly target the virus life-cycle and/or do not
require complete host IFN pathways to impart their antiviral
activity.
Despite the inhibition of arenavirus replication in cell culture
model systems, MY-24 did not reduce the viral burden
systemically nor in the various hamster or mouse tissues examined.
This may suggest that the mode of action in vivo is not based on
SAH hydrolase or other virus-direct antiviral activity. However,
we cannot rule out the possibility that at earlier time points, we
may have observed a significant reduction in serum and/or tissue
viral burden. It is conceivable that viral replication is abrogated at
earlier stages of the infection, yet eventually the titers reach peak
levels at the time of our analysis just prior to when the placebo-
treated mice begin to succumb to the disease. Additional sampling
times shortly after the onset of MY-24 treatment may uncover
differences in viral replication kinetics early during the course of
infection. Nevertheless, the present findings are consistent with the
idea that MY-24 may ameliorate disease by blunting host response
factors that play a role in disease pathogenesis occurring in
response to the viral infection.
In PICV-challenged hamsters, MY-24 significantly reduced
liver disease as indicated by greatly reduced levels of ALT. In the
AG129 mice treated therapeutically, the data are consistent with a
delay in disease pathogenesis as weight loss and visual signs of
disease were delayed in animals that received MY-24. This and the
hamster ALT findings support the theory that the compound is
attenuating the development of disease. A delay in the progression
of disease may facilitate the eventual clearance of the virus from
the system once the humoral immune response has more fully
developed up in the TCRV-infected mice. In hamsters, the delay
in disease pathogenesis does not lead to improved survival, only a
delay in time of death. Presumably, the hypercytokinemia that has
developed in response to the PICV infection in immune
competent animals ultimately triggers excessive vascular leakage
(Gowen et al. unpublished data), believed to be the fatal lesion in
cases of VHF [41,42].
Because our present studies only examined viral titers on day 8
of infection, studies to evaluate viral titers on day 14, 21 and 28 of
infection in MY-24-treated mice are necessary to determine when
the virus is cleared from the blood and tissues, and to assess anti-
TCRV neutralizing antibody levels. Moreover, future studies will
examine the effect of MY-24 treatment on aspartate aminotrans-
ferase (AST) levels in TCRV-infected mice. Elevation of systemic
concentration of AST is indicative of tissue damage and is a known
prognosticator of disease outcome in severe cases of Lassa fever
[14]. Lastly, our findings showed that in mice wherein treatment
was initiated on day 5 of infection, disease was less severe and the
onset of clinical signs of illness was delayed. This may be due to
MY-24 possibly dampening the exaggerated cytokine response
that may occur; however, starting treatment too soon may prevent
a robust early innate immune response. Thus, additional
experiments to investigate the contribution of an overzealous
proinflammatory response to mortality in the AG129 TCRV
mouse infection model, and the impact of MY-24 treatment on
this response, are warranted. These studies will hopefully provide
insights into the mechanism by which mice treated with MY-24
are able to survive TCRV challenge.
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